Compound 166
Identifiers
- Canonical SMILES:
COc1cccc2O[C@@H](C3=C(N(C)c4ncnn4[C@H]3c3ccc(Br)cc3)c12)c1ccc(Br)cc1
- InChi:
InChI=1S/C26H20Br2N4O2/c1-31-24-21-19(33-2)4-3-5-20(21)34-25(16-8-12-18(28)13-9-16)22(24)23(32-26(31)29-14-30-32)15-6-10-17(27)11-7-15/h3-14,23,25H,1-2H3/t23-,25+/m0/s1
- InChiKey:
CBAILBZVEPFBDC-UKILVPOCSA-N
External links
44549764 |
CHEMBL2347394 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
MDM2-Like / P53 | 6.52 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 578.00 g/mol | |||
HBA | 6 | |||
HBD | 0 | |||
HBA + HBD | 6 | |||
AlogP | 6.35 | |||
TPSA | 52.41 | |||
RB | 3 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4353 | BMS-394136 | DB12067 | |
0.3694 | GDC-0927 | DB14934 | |
0.3525 | Rocaglamide | DB15495 | |
0.3507 | Iclaprim | DB06358 | |
0.3507 | (S)-iclaprim | DB07938 | |
0.3507 | 5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine | DB08741 | |
0.3505 | Galicaftor | DB14894 | |
0.3493 | Didesmethylrocaglamide | DB15496 | |
0.3456 | LY-2881835 | DB15046 | |
0.3454 | Cannabichromene | DB14735 | |
0.3361 | Desvancosaminyl vancomycin | DB04529 | |
0.3344 | (4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium | DB02673 | |
0.3333 | Vancomycin | DB00512 | |
0.3313 | MK-1775 | DB11740 | |
0.3313 | Parsaclisib | DB14867 |